Clinical progress dominated the health and bio space, with a small-cap gene therapy trial and a licensing milestone sharing billing alongside a major pharma readout. The common thread was durability, of drug effect, of revenue, and of trial results holding up under follow-up scrutiny.
Genflow's SIRT6 therapy holds steady at three months
Genflow Biosciences (LON:GENF) confirmed that its dog longevity trial showed sustained efficacy, with three-month follow-up data holding steady on the SIRT6 gene therapy programme. The company also disclosed a fully funded delivery partnership with Acuitas Therapeutics, addressing one of the key technical hurdles in gene therapy administration. Shares in Genflow rose 2.56% to 2.0p on the update.
Aptamer Group books first licensing revenue
Aptamer Group (LON:APTA) reported 25% revenue growth alongside its first-ever licensing income, a milestone chief executive Dr Arron Tolley described as strategically significant for the business. The licensing income marks a shift for the group beyond service-based revenue toward royalty-style income streams tied to its Optimer binder technology. Aptamer shares traded at 0.475p.
Jemperli clears bar in rectal cancer study
GSK (LON:GSK) reported that its immunotherapy Jemperli met its primary goal in a phase II trial for dMMR/MSI-H locally advanced rectal cancer, with positive interim results raising the prospect that some patients could avoid chemotherapy, radiation and surgery altogether. The data adds to Jemperli's growing footprint in mismatch-repair-deficient tumours. GSK shares slipped 0.33% to 1955.0p.
